Immunofluorescent Imaging/Analysis Solution Quantifies Protein Biomarkers
By LabMedica International staff writers
Posted on 30 Nov 2011
An immunofluorescent imaging and analysis solution provides an improvement on traditional immunohistochemistry.Posted on 30 Nov 2011
The new product enables users to leverage the combined imaging and analysis power of Vectra 2 and AQUA technology, an image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.
Vectra 2 is an automated multiplexed and multispectral tissue-imaging platform. AQUA technology is capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, reproducible, and automated analysis to guide drug development and therapeutic decision-making.
Caliper Life Sciences (Hopkinton, MA, USA) and HistoRx (Branford, CT, USA) collaborated on the new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible immunohistochemistry results. Caliper will distribute the integrated product in the scientific market; the two companies are also exploring collaborations in diagnostics and clinical research.
AQUAServe is new server-based queuing software designed to enable “walk-away” operation for multiple specimens while retaining the full functionality of HistoRx's flagship AQUAnalysis software.
Caliper Life Sciences, a Perkin-Elmer Company, launched the new Vectra 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting held from November 12-16, 2011, in San Francisco (CA, USA)
"The Vectra 2 with AQUA technology represents a significant move forward for those interested in digital pathology with both brightfield and fluorescent capabilities," said Mark Gustavson, PhD, director of operations at HistoRx.
Related Links:
Caliper Life Sciences
HistoRx